Online Module - Pediatric GHD - Working Together to Ensure Success
Online Module - Pediatric GHD - Working Together to Ensure Success
The Endocrine Society and The France Foundation recently presented a program on pediatric growth hormone deficiency (GHD) titled "Working Together to Ensure Success." This program featured an expert panel that discussed challenges posed by GHD and how they can be addressed by health care providers.
The Endocrine Society and The France Foundation also produced a separate online module on the topic of GHD. While similar to the "Working Together to Ensure Success" webinar, this module, also led by experts in the field, contains valuable material for internal medicine and adult practitioners who may treat patients who were previously treated for pediatric GHD.
This educational initiative is intended for pediatric and general endocrinologists, family physicians, pediatricians, nurse practitioners, and physician assistants who are managing pediatric patients with GHD.
Upon completing this activity, learners will be able to:
- Review the safety and efficacy data of the rhGH therapies available for the management of GHD in pediatric patients
- Assess novel and emerging rhGH agents and clinical implications for management of GHD in pediatric patients
- Discuss the importance and clinical implications of adherence to rhGH therapy in GHD in pediatric patients
Introduction - Craig A. Alter, MD
Persistent GHD: The Stakes Are High - Craig Alter, MD
Long-acting GH preparations - Bradley S. Miller, MD, PhD
What’s Getting in the Way? Common Barriers to Treatment Success - Adda Grimberg, MD
Safety of Growth Hormone Therapy - Adda Grimberg, MD
Craig A. Alter, MD – Program Chair
Children's Hospital of Philadelphia
Adda Grimberg, MD
Perelman School of Medicine, University of Pennsylvania
Bradley S. Miller, MD, PhD
University of Minnesota Masonic Children's Hospital
STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s guideline task force.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion. The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The Endocrine Society has reviewed these relationships to determine which are relevant to the content of this activity and resolved any identified conflicts of interest for these individuals.
The faculty reported the following relevant financial relationship(s) during the content development process for this activity:
- Craig A. Alter, MD: Advisory Board Member: Novo Nordisk; Consultant: OPKO Health
- Adda Grimberg, MD: Grant Recipient: Pfizer Inc.
- Bradley S. Miller, MD, PhD: Consultant: Ascendis Pharma, Abbvie, Biomarin, Orchard, Pfizer Inc., Novo Nordisk, Sandoz Inc., Sanofi Genzyme, Tolmar and Vertice; Research Investigator: Alexion, Abbvie, Amgen, Ascendis, Lumos Pharma, Novo Nordisk, OPKO Health, Pfizer Inc., Sandoz, and Tolmar. He will discuss off-label use of medications since these medications are being developed.
The following SPC member who planned and reviewed content for this activity reported relevant financial relationships:
- Andjela T. Drincic, MD: Advisory Board Member: Corcept Therapeutics
The following SPC members reported no relevant financial relationships: Howard S. Blank, MD; Beret Ann Casey, MD; Lediya Cheru, MD; Marcelo Correia, MD, PhD; Angela M. Leung, MD; Kelly Lauter Roszko, MD, PhD; Virginia D. Sarapura, MD; Soleymani Taraneh, MD; Savitha Subramanian, MD
The staff involved in the development of this CME activity reported no relevant financial relationships.
DISCLAIMERS USE OF PROFESSIONAL JUDGMENT: The educational content in this activity relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.
DRUGS AND DOSAGES: When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
POLICY ON UNLABELED/OFF-LABEL USE: The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.
PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.
ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This educational activity is supported by educational grants from Pfizer Inc and Sandoz Inc.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Endocrine Society and The France Foundation. The Endocrine Society is accredited by the ACCME to provide continuing medical education for physicians.
AMA PRA Category 1 Credit:
The Endocrine Society designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. While offering CME credits noted above, this program is not intended to provide extensive training or certification in the field.
Please note that while other accrediting bodies accept AMA PRA Category 1 credit, we can only award and report this credit for MDs/DOs. For those outside of this accreditation, please complete the participation evaluation and use that certificate as proof of attendance to submit to your accrediting body.
American Board of Pediatrics (ABP) Maintenance of Certification (MOC):
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 points in the American Board of Pediatrics’ (ABP) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABP MOC credit.
Participants must complete the activity evaluation by May 31, 2022.
For questions about content or obtaining CME credit, please contact the Endocrine Society at email@example.com.
- 1.00 ABP MOC
- 1.00 AMA PRA Category 1 Credits™